Ausun Pharm(SH:603229) Ge Long Hui·2025-09-16 08:15Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in the company's product portfolio [1]. Group 1: Product Approval - The drug registration certificate (Certificate No.: 2025S02736) is for Imatinib Mesylate Tablets, which is the world's first targeted molecular therapy for cancer [1]. - Imatinib Mesylate is indicated for patients with chronic myeloid leukemia (CML) in the acute phase, accelerated phase, or chronic phase after failure of alpha-interferon treatment, as well as for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1]. Group 2: Mechanism of Action - The active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively inhibits the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function [1]. - This mechanism helps to suppress the abnormal proliferation of white blood cells and also binds to the active site of tyrosine kinase, blocking its activity [1].